Supply of weight loss drug Wegovy expected to improve in next few months, company says

  • 📰 NBCNews
  • ⏱ Reading Time:
  • 28 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 14%
  • Publisher: 86%

Россия Новости Новости

Россия Последние новости,Россия Последние новости

Following widespread shortages due to increasing popularity, the maker of the popular weight loss drug Wegovy will ramp up production of the drug.

on Dec. 28 that all dosages of the drug would be available again after supply issues, but added that it may take time for the drug to arrive at pharmacies from distribution centers.

There continues to be “pent up demand” for Wegovy, but Novo Nordisk expects this to become less of a problem as more supply of the drug becomes available over the next few months, Jorgensen said. “We are obviously encouraged by the trendline we see, but we also do believe there will be a normalization of that," he said.

Wegovy, or semaglutide, is part of a class of drugs called GLP-1 agonists. They mimic a hormone that helps reduce food intake and cut appetite. In clinical trials, Wegovy was shown to reduce body weight by

 

Спасибо за ваш комментарий. Ваш комментарий будет опубликован после проверки

I thought wegovy was an insulin analogue for Diabetes type II patients?

Get off your ass and exercise you lazy losers

Maybe people can stop using ADHD medicine for weight loss. What most people don't realize is that some ADHD medicines are suppressants. That's one of the factors as to why there is a shortage of medication for kids with ADHD.

The illegals are crowding the street here in Manhattan New York! They refuse to leave the free 4 star hotel until we give them free high rise apartments! I say give them to them and bankrupt New York!

The Only Drug That Makes You Lose Weight Is Cocaine

Big Pharma Drugs Don't Work

No thanks

Мы обобщили эту новость, чтобы вы могли ее быстро прочитать.Если новость вам интересна, вы можете прочитать полный текст здесь Прочитайте больше:

 /  🏆 10. in RU

Россия Последние новости, Россия Последние новости

Similar News:Вы также можете прочитать подобные новости, которые мы собрали из других источников новостей

Drugmaker Pfizer starts low with 2023 earnings forecastPfizer expects sales of both the vaccine Comirnaty and the treatment Paxlovid to tumble next year before starting to rebound. That drop was anticipated by analysts, but the degree of the expected fall was not.
Источник: wjxt4 - 🏆 246. / 63 Прочитайте больше »